Latest Morning Briefing Stories
The Money And Politics Of Prescription Drugs: What You Need To Know
America spends about as much on prescription drugs as all the revenues of the three big car makers combined. Tracking where the money goes is hard. PolitiFact has some charts to help.
Drug Industry Patents Go Under Senate Judiciary Committee’s Microscope
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
Is Insulin’s High Cost Keeping Diabetes Patients From Taking Their Medicine?
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It’s “within spitting distance of something that’s true,” said one health economist. But our fact check found it wasn’t quite there.
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Doughnut Hole Is Gone, But Medicare’s Uncapped Drug Costs Still Bite Into Budgets
Beneficiaries pay 25 percent of the price of their brand-name drugs until they reach $5,100 in out-of-pocket costs. After that, their obligation drops to 5 percent. But it never disappears.
Analysis: Why Americans Shouldn’t Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.
Podcast: KHN’s ‘What The Health?’ The Karma Of Cutting Medicare
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump’s budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA’s crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Lawmakers United Against High Drug Prices Bare Partisan Teeth
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
Ciudades y condados seguirán importando medicamentos, a pesar de alertas de la FDA
Varios estados, entre ellos Florida y Nueva York, dijeron que continuarán usando una compañía canadiense para ofrecer a sus empleados medicamentos recetados a bajo precio.
Pacientes experimentan con drogas recetadas para luchar contra la vejez
Aún no se han realizado ensayos clínicos rigurosos a gran escala para estudiar el proceso de envejecimiento. Así y todo, pacientes experimentan con drogas para detener el paso del tiempo.
